



FOR IMMEDIATE RELEASE

Cato Research Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2018

Durham, NC, April 21, 2018— [Cancer Advances Inc.](#), a wholly owned subsidiary of Cato Holding Company, is helping create awareness and raise funds in the fight against pancreatic cancer, the nation's third leading cause of cancer death, by sponsoring and participating in PurpleStride Raleigh-Durham 2018 5K Run & Family-Friendly Walk. Employees and their families have come together to create Cato Research Cancer Advances Team and hope to raise more funding beyond their sponsorship to support the mission of the Pancreatic Cancer Action Network to advance research, support patients, and create hope.

PurpleStride Raleigh-Durham 2017 5K Run & Family-Friendly Walk will take place today at the NC State Centennial Campus. This community event is planned entirely by local volunteers and will pay tribute to loved ones who have succumbed to the disease, as well as honor those who are currently fighting pancreatic cancer.

"We are proud to sponsor and take part in PurpleStride to raise awareness and research funds for Pancreatic Cancer in hopes of finding a cure for this deadly disease," said Lynda Sutton, president of Cancer Advances and Cato Research.

Each person who dies from pancreatic cancer – an estimated 44,330 Americans this year – is a mother, daughter, father, son, sister, brother, colleague or friend. PanCAN fights for every one of them.

To join Cato Research Cancer Advances Team or to donate, visit our page: http://support.pancan.org/site/TR/PurpleStride/PurpleStride?team_id=11791&pg=team&fr_id=1427

Cancer Advances is DEDICATED to enhancing the immune system and augmenting human quality of life by targeting the progression of gastrointestinal cancers.

Cancer Advances
P | 919-361-2162
E | info@canceradvancesinc.com
www.canceradvancesinc.com



About Cancer Advances Inc.

Cancer Advances Inc., a wholly owned subsidiary of Cato Holding Company, is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

Please visit our product page for more information on what is in development: <http://www.canceradvancesinc.com/product.html>

Contact: Lynda Sutton

President [Cancer Advances, Inc.](http://www.canceradvancesinc.com)

Phone: 919-361-2162 Email: info@canceradvancesinc.com

Cancer
Advances is
DEDICATED
to enhancing
the immune system
and augmenting
human quality of life by
targeting the progression
of gastrointestinal cancers.

Cancer Advances

P | 919-361-2162

E | info@canceradvancesinc.com

www.canceradvancesinc.com